Oncology Corporate Profile
VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases. The Company's lead product candidate is VTX-2337, a small molecule TLR8 agonist for the treatment of cancer. VentiRx has an exclusive, world-wide collaboration with Celgene Corporation for VTX-2337. VentiRx is a privately held organization based in Seattle, Washington.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|VTX-2337||toll-like Receptor 8 (TLR8)||Ovarian cancer||II|
|VTX-2337 (+ cetuximab )||toll-like Receptor 8 (TLR8)||Squamous cell cancer of the head and neck (SCCHN)||II|
|VTX-2337||toll-like Receptor 8 (TLR8)||Various cancer types||I|
View additional information on product candidates here »